Jin Hai Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jin Hai Zheng has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Yanxia Guo
The Affiliated Xiangtan Central Hospital of Hunan University, School of Biomedical Sciences Hunan University Changsha China
7 shared publicationsXiaoqing Liu
The Affiliated Xiangtan Central Hospital of Hunan University, School of Biomedical Sciences Hunan University Changsha China
6 shared publicationsWenzhi Tan
The Affiliated Xiangtan Central Hospital of Hunan University, School of Biomedical Sciences Hunan University Changsha China
5 shared publicationsYu Chen
The Affiliated Xiangtan Central Hospital of Hunan University, School of Biomedical Sciences Hunan University Changsha China
5 shared publicationsYujie Sun
School of Biomedical Sciences, Hunan University, Changsha 410082, China; Hunan Key Laboratory of Animal Models and Molecular Medicine, Hunan University, Changsha 410082, Hunan, China
5 shared publicationsJinling Liu
School of Biomedical Sciences, Hunan University, Changsha 410082, China
4 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (8) , 102913
Synthetically engineered probiotic suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling
- 18 August 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (8) , 102913
Open AccessSynthetically engineered probiotic suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling
- 18 December 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 390, 114547
Glutathione-responsive self-assembling peptide-coated Salmonella for antitumor therapy
- 18 December 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 390, 114547
Glutathione-responsive self-assembling peptide-coated Salmonella for antitumor therapy
- 11 August 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (11) , 2080-2093
S100a8/a9 regulated by LPS/TLR4 axis plays an important role in Salmonella‐based tumor therapy and host defense
Bacteria are ideal anticancer agents and carriers due to their unique capabilities that are convenient in genetic manipulation, tumor‐specific targeting, and deep‐tissue penetration. However, the specific molecular mechanisms of bacteria‐mediated cancer therapy (BMCT) have not been clarified. In this study, we found that TLR4 signaling pathway is critical for Salmonella‐mediated tumor targeting, tumor suppression, and liver and spleen protection. TLR4 knockout in mice decreased the levels of cytokines and chemokines, such as S100a8, S100a9, TNF‐α, and IL‐1β, in tumor microenvironments (TMEs) after Salmonella treatment, which inhibited tumor cell death and nutrient release, led to reduced bacterial contents in tumors and attenuated antitumor efficacy in a negative feedback manner. Importantly, we found that S100a8 and S100a9 played a leading role in Salmonella‐mediated cancer therapy (SMCT). The antitumor efficacy was abrogated and liver damage was prominent when blocked with a specific inhibitor. These findings elucidated the mechanism of Salmonella‐mediated tumor targeting, suppression, and host antibacterial defense, providing insights into clinical cancer therapeutics.
- 11 August 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (11) , 2080-2093
S100a8/a9 regulated by LPS/TLR4 axis plays an important role in Salmonella‐based tumor therapy and host defense
Bacteria are ideal anticancer agents and carriers due to their unique capabilities that are convenient in genetic manipulation, tumor‐specific targeting, and deep‐tissue penetration. However, the specific molecular mechanisms of bacteria‐mediated cancer therapy (BMCT) have not been clarified. In this study, we found that TLR4 signaling pathway is critical for Salmonella‐mediated tumor targeting, tumor suppression, and liver and spleen protection. TLR4 knockout in mice decreased the levels of cytokines and chemokines, such as S100a8, S100a9, TNF‐α, and IL‐1β, in tumor microenvironments (TMEs) after Salmonella treatment, which inhibited tumor cell death and nutrient release, led to reduced bacterial contents in tumors and attenuated antitumor efficacy in a negative feedback manner. Importantly, we found that S100a8 and S100a9 played a leading role in Salmonella‐mediated cancer therapy (SMCT). The antitumor efficacy was abrogated and liver damage was prominent when blocked with a specific inhibitor. These findings elucidated the mechanism of Salmonella‐mediated tumor targeting, suppression, and host antibacterial defense, providing insights into clinical cancer therapeutics.
- 4 July 2024
- Published by Elsevier in Life Sciences
- Vol. 352, 122897
Path to bacteriotherapy: From bacterial engineering to therapeutic perspectives
- 4 July 2024
- Published by Elsevier in Life Sciences
- Vol. 352, 122897
Path to bacteriotherapy: From bacterial engineering to therapeutic perspectives
- Open Access
- 2 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Hidden diversity and potential ecological function of phosphorus acquisition genes in widespread terrestrial bacteriophages
Phosphorus (P) limitation of ecosystem processes is widespread in terrestrial habitats. While a few auxiliary metabolic genes (AMGs) in bacteriophages from aquatic habitats are reported to have the potential to enhance P-acquisition ability of their hosts, little is known about the diversity and potential ecological function of P-acquisition genes encoded by terrestrial bacteriophages. Here, we analyze 333 soil metagenomes from five terrestrial habitat types across China and identify 75 viral operational taxonomic units (vOTUs) that encode 105 P-acquisition AMGs. These AMGs span 17 distinct functional genes involved in four primary processes of microbial P-acquisition. Among them, over 60% (11/17) have not been reported previously. We experimentally verify in-vitro enzymatic activities of two pyrophosphatases and one alkaline phosphatase encoded by P-acquisition vOTUs. Thirty-six percent of the 75 P-acquisition vOTUs are detectable in a published global topsoil metagenome dataset. Further analyses reveal that, under certain circumstances, the identified P-acquisition AMGs have a greater influence on soil P availability and are more dominant in soil metatranscriptomes than their corresponding bacterial genes. Overall, our results reinforce the necessity of incorporating viral contributions into biogeochemical P cycling.
- 2 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessHidden diversity and potential ecological function of phosphorus acquisition genes in widespread terrestrial bacteriophages
Phosphorus (P) limitation of ecosystem processes is widespread in terrestrial habitats. While a few auxiliary metabolic genes (AMGs) in bacteriophages from aquatic habitats are reported to have the potential to enhance P-acquisition ability of their hosts, little is known about the diversity and potential ecological function of P-acquisition genes encoded by terrestrial bacteriophages. Here, we analyze 333 soil metagenomes from five terrestrial habitat types across China and identify 75 viral operational taxonomic units (vOTUs) that encode 105 P-acquisition AMGs. These AMGs span 17 distinct functional genes involved in four primary processes of microbial P-acquisition. Among them, over 60% (11/17) have not been reported previously. We experimentally verify in-vitro enzymatic activities of two pyrophosphatases and one alkaline phosphatase encoded by P-acquisition vOTUs. Thirty-six percent of the 75 P-acquisition vOTUs are detectable in a published global topsoil metagenome dataset. Further analyses reveal that, under certain circumstances, the identified P-acquisition AMGs have a greater influence on soil P availability and are more dominant in soil metatranscriptomes than their corresponding bacterial genes. Overall, our results reinforce the necessity of incorporating viral contributions into biogeochemical P cycling.
- Open Access
- 1 January 2023
- Published by Ivyspring International Publisher in Theranostics
- Vol. 13 (15) , 5546-5560
Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy
Background and rationale: Attenuated Salmonella typhimurium VNP20009 has been used to treat tumor-bearing mice and entered phase I clinical trials. However, its mild anticancer effect in clinical trials may be related to insufficient bacterial colonization and notable adverse effects with increasing dosages. Guanosine 5′-diphosphate-3′-diphosphate (ppGpp) synthesis-deficient Salmonella is an attenuated strain with good biosafety and anticancer efficacy that has been widely investigated in various solid cancers in preclinical studies. Integration of the advantages of these two strains may provide a new solution for oncolytic bacterial therapy.
- 1 January 2023
- Published by Ivyspring International Publisher in Theranostics
- Vol. 13 (15) , 5546-5560
Open AccessEngineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy
Background and rationale: Attenuated Salmonella typhimurium VNP20009 has been used to treat tumor-bearing mice and entered phase I clinical trials. However, its mild anticancer effect in clinical trials may be related to insufficient bacterial colonization and notable adverse effects with increasing dosages. Guanosine 5′-diphosphate-3′-diphosphate (ppGpp) synthesis-deficient Salmonella is an attenuated strain with good biosafety and anticancer efficacy that has been widely investigated in various solid cancers in preclinical studies. Integration of the advantages of these two strains may provide a new solution for oncolytic bacterial therapy.
- 10 October 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 351, 860-871
Photodynamic therapy-improved oncolytic bacterial immunotherapy with FAP-encoding S. typhimurium
- 10 October 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 351, 860-871
Photodynamic therapy-improved oncolytic bacterial immunotherapy with FAP-encoding S. typhimurium
- Open Access
- 29 June 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 914575
Comparison of Anticancer Activities and Biosafety Between Salmonella enterica Serovar Typhimurium ΔppGpp and VNP20009 in a Murine Cancer Model
Salmonella Typhimurium defective in guanosine 5′-diphosphate-3′-diphosphate (ppGpp) synthesis (ΔppGpp) is an attenuated strain with good biosafety and excellent anticancer efficacy. It has been widely applied in preclinical studies of anticancer therapy for various types of solid cancer. VNP20009 is another genetically modified auxotrophic strain with 108-kb deletion, purI−, msbB−, and many single nucleotide polymorphisms (SNPs); it has shown promising therapeutic efficacy in various preclinical tumor models and entered phase I clinical trials. Here, the invasion activities and virulence of ΔppGpp were obviously lower than those of the VNP20009 strain when tested with cancer cells in vitro. In addition, the MC38 tumor-bearing mice showed comparable cancer suppression when treated with ΔppGpp or VNP20009 intravenously. However, the ΔppGpp-treated mice showed 16.7% of complete cancer eradication and prolonged survival in mice, whereas VNP20009 showed higher toxicity to animals, even with equal tumor size individually. Moreover, we found decreased levels of inflammatory cytokines in circulation but strengthened immune boost in tumor microenvironments of ΔppGpp-treated mice. Therefore, the engineered ΔppGpp has high potential for cancer therapeutics, and it is a promising option for future clinical cancer therapy.
- 29 June 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 914575
Open AccessComparison of Anticancer Activities and Biosafety Between Salmonella enterica Serovar Typhimurium ΔppGpp and VNP20009 in a Murine Cancer Model
Salmonella Typhimurium defective in guanosine 5′-diphosphate-3′-diphosphate (ppGpp) synthesis (ΔppGpp) is an attenuated strain with good biosafety and excellent anticancer efficacy. It has been widely applied in preclinical studies of anticancer therapy for various types of solid cancer. VNP20009 is another genetically modified auxotrophic strain with 108-kb deletion, purI−, msbB−, and many single nucleotide polymorphisms (SNPs); it has shown promising therapeutic efficacy in various preclinical tumor models and entered phase I clinical trials. Here, the invasion activities and virulence of ΔppGpp were obviously lower than those of the VNP20009 strain when tested with cancer cells in vitro. In addition, the MC38 tumor-bearing mice showed comparable cancer suppression when treated with ΔppGpp or VNP20009 intravenously. However, the ΔppGpp-treated mice showed 16.7% of complete cancer eradication and prolonged survival in mice, whereas VNP20009 showed higher toxicity to animals, even with equal tumor size individually. Moreover, we found decreased levels of inflammatory cytokines in circulation but strengthened immune boost in tumor microenvironments of ΔppGpp-treated mice. Therefore, the engineered ΔppGpp has high potential for cancer therapeutics, and it is a promising option for future clinical cancer therapy.
- Open Access
- 1 February 2022
- Published by Elsevier in Molecular Therapy
- Vol. 30 (2) , 662-671
Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium
- 1 February 2022
- Published by Elsevier in Molecular Therapy
- Vol. 30 (2) , 662-671
Open AccessTargeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium